An oral surgeon's evaluation of Emdogain.
A product developed by researchers in Sweden (Biora AB Malmo, Sweden) has been approved by the United States Food and Drug Administration for use in the regeneration of periodontal attachment apparatus. Enamel matrix protein (Emdogain) has been shown to be effective in animal and human studies. This report documents a series of 19 clinical trials to help retain "hopeless" teeth referred for extraction. It was offered as an alternative to extraction. The techniques used involved a departure from the method specifically recommended by the manufacturer. Seventeen of the 19 teeth treated showed significant improvement with decreased mobility, improved attachment levels and new bone on follow-up radiographic examination.
Trieger
Norman
N
D016301:Alveolar Bone Loss / Q000188:drug therapy* / Q000601:surgery*; D001861:Bone Regeneration / Q000187:drug effects*; D025021:Cementogenesis / Q000187:drug effects; D003746:Dental Enamel Proteins / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D013357:Subgingival Curettage
D003746:Dental Enamel Proteins; C109069:enamel matrix proteins